Description

• Broad-spectrum oral fluoroquinolone antibacterial for dogs.



• Effective for treating skin and soft-tissue infections in dogs and for urinary tract infections in dogs.

• Treating infections in dogs associated with bacteria susceptible to marbofloxacin.



• Effective in treating bacterial skin and soft-tissue infections in dogs and canine urinary tract infections (cystitis) associated with bacteria susceptible to marbofloxacin.

• Powerful antibacterial therapy resource for small-animal practitioners.



• Excellent safety profile.



• Convenient once-a-day dosing and easy-to-swallow film-coated tablets improve client compliance.



• Available in 4 potencies for flexible dosing for small to giant-sized breeds.



• Maintains high plasma concentrations longer than any other fluoroquinolone, based on label comparisons of small animal veterinary fluoroquinolones.

• Recommended dosage for oral administration to dogs is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb.



• For treatment of skin and soft-tissue infections, ZENIQUIN Tablets should be given for 2 to 3 days beyond cessation of clinical signs for a maximum of 30 days. For treatment of urinary tract infections, ZENIQUIN Tablets should be administered for at least 10 days. If no improvement is noted within 5 days, diagnosis should be reevaluated and a different course of therapy considered.

• Marbofloxacin and other quinolones have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of most species tested, particularly dogs. Marbofloxacin is contraindicated in immature dogs during the rapid growth phase (small and medium breeds up to 8 months of age, large breeds up to 12 months of age and giant breeds up to 18 months of age).



• Marbofloxacin is contraindicated in dogs known to be hypersensitive to quinolones.



• The following clinical signs were reported during clinical field studies in dogs receiving marbofloxacin at dosages up to 2.5 mg/lb daily: decreased or loss of appetite (5.4%), decreased activity (4.4%), and vomiting (2.9%). The following signs were reported in less than 1% of cases in dogs: increased thirst, soft stool/diarrhea, behavioral changes, shivering/shaking/tremors and ataxia.



• Federal law restricts this drug to use by or on order of a licensed veterinarian.



• Federal law prohibits the extra-label use of this drug in food-producing animals.